MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

NICE recommends natalizumab as a new treatment for adults with highly active relapsing-remitting multiple sclerosis ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

As the multiple sclerosis (MS) population ages, managing the condition can bring new challenges. For one woman, working closely with her doctor, exploring treatment options, and finding the right ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Artificial intelligence (AI), using a simple blood test combined with standard brain images has, for the first time, been ...

NICE has recommended the drug, natalizumab, as an option for adults with relapsing-remitting MS (RRMS) that remains highly active after a full course of at least one disease-modifying therapy, and for ...